Medical Condition News

RSS

Consumption of caffeinated coffee and alcohol reduces risk of contracting late onset diabetes

In a very large cohort of African-American women in the US, the association between the consumption of alcohol, tea, and coffee and the development of type 2 diabetes mellitus (late onset diabetes) was studied for 12 years. Tea and decaffeinated coffee showed no relation with diabetes, but the regular moderate intake of both caffeinated coffee and alcohol appeared to reduce the risk of contracting late onset diabetes significantly.

30 Sep 2010

International scientists meet to progress cancer research

THE deliberations of a small group of specialists, meeting in Edinburgh tomorrow, will help make progress in cancer research all over the world.On Thursday (September 30) nineteen international scientists are due to get round the table to decide which cancer research projects, from the 125 in front of them, will benefit from a grants package totalling more than £4 million.

30 Sep 2010

Natural remedy for eczema

Eczema Free Forever provides answers with practical, homemade and natural solutions, that the eczema suffering population in any part of the world can easily perform in the comfort of their home.

30 Sep 2010

Agilent introduces SureSelect Kinome Target Enrichment Kit to focus next-generation sequencing studies

Agilent Technologies Inc. today introduced the SureSelect Kinome Target Enrichment Kit, enabling researchers to focus next generation sequencing studies on expressed kinases (the kinome). Researchers increasingly are looking at human kinases as a rich, proven source of biomarkers as well as potential drug targets for cancers and other diseases.

30 Sep 2010

Concentric Medical commences TREVO Study of Stentriever technology in ischemic stroke patients

Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced the start of the TREVO Study. The first patients were enrolled and successfully treated at the Hospital Clinic de Barcelona by the Neuroradiology team of Drs. Juan Macho and Jordi Blasco.

30 Sep 2010

Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial

Repligen Corporation reported today that it has completed enrollment of patients in its Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.

30 Sep 2010

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.

30 Sep 2010

New approach to prevent psychotic symptoms

New research has linked psychosis with an abnormal relationship between two signalling chemicals in the brain. The findings, published in tomorrow's edition of the journal Biological Psychiatry, suggest a new approach to preventing psychotic symptoms, which could lead to better drugs for schizophrenia.

30 Sep 2010

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

The pharmaceutical division of the company Neuron BPh and the research group of Organometallic Chemistry and Homogeneous Catalysis of the Universitat Jaume I, have evaluated the possible applications of a series of ruthenium compounds for their future use in the treatment of neurodegenerative disease such as Alzheimer.

30 Sep 2010

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).

30 Sep 2010

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering Corporation) to develop and commercialize AV-299 (also known as SCH 900105), its anti-hepatocyte growth factor (HGF) antibody candidate.

30 Sep 2010

FDA grants Type B meeting to review Phase III pivotal efficacy protocols for Androxal

Repros Therapeutics Inc. today announced that the Company has been granted a Type B meeting to be held on November 8, 2010 with the Division of Reproductive and Urologic Products to review the Company's Phase III pivotal efficacy protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.

30 Sep 2010

Best P.A.D. Research Awards honor investigators for research on peripheral arterial disease

The Peripheral Arterial Disease (P.A.D.) Coalition presented the Coalition's second annual Best P.A.D. Research Awards to the top three research papers on P.A.D. published in 2009 at the organization's Seventh Annual Meeting in Alexandria, VA last week. The Best P.A.D. Research Awards honor the work of investigators and acknowledge the creation of new clinical research relevant to the understanding and/or treatment of peripheral arterial disease.

30 Sep 2010

Cardium expands wound healing and tissue regeneration portfolio

Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.

30 Sep 2010

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

Tengion, Inc. presented new research data yesterday in a podium presentation at the 2nd Annual Symposium on Stem Cell Translation of the International Society for Cellular Therapy (ISCT) in San Francisco. The presentation highlighted new results from Tengion's Neo-Kidney Augment development program demonstrating success with an autologous cellular therapy approach to kidney regeneration in a rodent model of obesity, diabetes and hypertension.

30 Sep 2010

PAF launches new Colorectal Financial Aid Fund

The Patient Advocate Foundation (PAF) a national non-profit resolving patient access to health care issues, medical financial limitations, insurance denials and multiple government program enrollments, including Medicaid and Social Security Disability Income announced today that it launched a new Colorectal Financial Aid Fund (FAF) beginning September 28, 2010.

30 Sep 2010

Tryton reports positive interim results from Side Branch Stent System study

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced interim six-month results from a symposium during the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference in Washington, D.C.

30 Sep 2010

Multi-disciplinary approach increases breast cancer survival rate: Study

Advances in screening for disease detection, better surgical techniques available to more women, and an increased number of therapies that reduce the risk of relapse in patients with both locally advanced and early stage disease, have collectively contributed to dramatic improvements in breast cancer's survival rates, according to a review of 60 years of patient records at The University of Texas MD Anderson Cancer Center.

30 Sep 2010

Penn Medicine selected as study site for PPMI

The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.

30 Sep 2010

New online CDSMP program launched to battle against chronic illnesses

Taking the battle against the national epidemic of chronic illnesses to the Internet, the National Council on Aging (NCOA) is making Better Choices, Better Health, the online version of the internationally recognized Chronic Disease Self Management Program (CDSMP), available free for people in California and six other states Hawaii, Iowa, Maine, Massachusetts, New Jersey, and Oregon.

30 Sep 2010

Medical Condition News

Consumption of caffeinated coffee and alcohol reduces risk of contracting late onset diabetes

International scientists meet to progress cancer research

Natural remedy for eczema

Agilent introduces SureSelect Kinome Target Enrichment Kit to focus next-generation sequencing studies

Concentric Medical commences TREVO Study of Stentriever technology in ischemic stroke patients

Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

New approach to prevent psychotic symptoms

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

FDA grants Type B meeting to review Phase III pivotal efficacy protocols for Androxal

Best P.A.D. Research Awards honor investigators for research on peripheral arterial disease

Cardium expands wound healing and tissue regeneration portfolio

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

PAF launches new Colorectal Financial Aid Fund

Tryton reports positive interim results from Side Branch Stent System study

Multi-disciplinary approach increases breast cancer survival rate: Study

Penn Medicine selected as study site for PPMI

New online CDSMP program launched to battle against chronic illnesses

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News